MicroRNA‑16‑5p regulates cell survival, cell cycle and apoptosis by targeting AKT3 in prostate cancer cells.
Apoptosis
/ genetics
Carcinogenesis
/ genetics
Cell Cycle
/ drug effects
Cell Line, Tumor
Cell Survival
/ drug effects
Computational Biology
Datasets as Topic
Gene Expression Regulation, Neoplastic
Humans
Male
MicroRNAs
/ agonists
Prostate
/ pathology
Prostatic Neoplasms
/ genetics
Proto-Oncogene Proteins c-akt
/ genetics
microRNA-16-5p
cell survival
cell cycle
apoptosis
prostate cancer
Journal
Oncology reports
ISSN: 1791-2431
Titre abrégé: Oncol Rep
Pays: Greece
ID NLM: 9422756
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
received:
18
02
2020
accepted:
11
06
2020
entrez:
25
7
2020
pubmed:
25
7
2020
medline:
22
5
2021
Statut:
ppublish
Résumé
Prostate cancer (PCa) is a malignancy with the highest morbidity rate in 105 countries worldwide and was a major cause of cancer‑associated death in men in 2018. Accumulating evidence suggests that microRNAs (miRNAs/miRs) have important functions in the carcinogenesis of PCa, and may provide novel treatment targets. Previous studies have indicated that miR‑16‑5p is associated with PCa. However, the relevance and importance of miR‑16‑5p in PCa carcinogenesis are still not completely understood. In the current study, we aimed to investigate the role and mechanism of miR‑16‑5p in PCa carcinogenesis. The results showed that miR‑16‑5p was markedly downregulated in PCa cells, and MTS assay, colony formation, flow cytometric analyses demonstrated that miR‑16‑5p inhibited PCa cell survival, regulated cell cycle distribution and induced apoptosis. Moreover, luciferase reporter assay and western blot analysis showed that miR‑16‑5p directly targets AKT3 (AKT serine/threonine kinase 3), which is associated with PCa carcinogenesis, and the effects of the downregulation of AKT3 were similar to the effects of upregulation of miR‑16‑5p in PC‑3 cells. In conclusion, our data clarify that miR‑16‑5p has anticancer functions in PCa cells, and our findings provide experimental evidence to highlight the potential value of miR‑targeting treatment strategies for PCa.
Identifiants
pubmed: 32705237
doi: 10.3892/or.2020.7682
doi:
Substances chimiques
MIRN16 microRNA, human
0
MicroRNAs
0
AKT3 protein, human
EC 2.7.11.1
Proto-Oncogene Proteins c-akt
EC 2.7.11.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM